WINDLAS BIOTECH LIMITED
WINDLAS · General/Diversified · NSE
₹868
Current Market Price
Fair Value (DCF)
₹473
Margin of Safety
-45.5%
Updated 20h ago
YieldIQ Score
47/100
Piotroski F-Score
5/9
Economic Moat
Moderate
Confidence
37%
ROE
—
Debt/Equity
0.06
WACC
11.1%
Market Cap
₹1,831 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
16.5%
Return on capital employed
EV / EBITDA
14.5×
Enterprise multiple
Debt / EBITDA
0.3×
Leverage vs earnings
Interest Coverage
19.2×
EBIT covers interest
Current Ratio
2.11×
Short-term liquidity
Asset Turnover
0.99×
Revenue per ₹ of assets
Revenue CAGR (3Y)
17.7%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹867.55
Bear case
₹284.17
MoS -205.3%
Base case
₹473.08
MoS -83.4%
Bull case
₹597.37
MoS -45.2%
Ratio Trends
WINDLAS · last 4 annual periods
ROE
12.1%
ROCE
20.8%
Operating Margin
—
Debt / Equity
0.06×
PE
11.2×
EV / EBITDA
6.8×
Historical Financials
WINDLAS · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹463 Cr | ₹511 Cr | ₹629 Cr | ₹755 Cr | +17.7% |
| EBITDA | ₹59.1 Cr | ₹70.2 Cr | ₹91.6 Cr | ₹112 Cr | +23.8% |
| EBIT | ₹47.5 Cr | ₹15.2 Cr | ₹22.8 Cr | — | -21.6% |
| PAT | ₹38.1 Cr | ₹42.6 Cr | ₹58.2 Cr | ₹61.0 Cr | +17.0% |
| EPS (diluted) | ₹18.81 | ₹5.37 | ₹8.12 | — | -24.4% |
| CFO | ₹9.1 Cr | ₹61.0 Cr | ₹109 Cr | ₹68.2 Cr | +95.5% |
| CapEx | ₹-14.8 Cr | ₹-70.9 Cr | ₹-37.7 Cr | ₹-52.2 Cr | — |
| FCF | ₹-5.7 Cr | ₹-9.9 Cr | ₹71.3 Cr | ₹16.0 Cr | — |
| Total Assets | ₹491 Cr | ₹529 Cr | ₹626 Cr | ₹760 Cr | +15.7% |
| Total Debt | ₹6.6 Cr | ₹5.0 Cr | ₹3.6 Cr | ₹32.6 Cr | +70.0% |
| Shareholders' Equity | ₹395 Cr | ₹402 Cr | ₹450 Cr | ₹506 Cr | +8.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
WINDLAS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| INDOCO INDOCO | — | — | Pending | -7.2% | — |
| AMRUTANJAN AMRUTAJAN HEALTH LTD | -46.1% | 45 | Above Fair Value | 15.6% | — |
| MOREPENLAB MOREPEN LAB. LTD | -31.6% | 43 | Above Fair Value | 9.9% | — |
| HIKAL HIKAL LIMITED | -15.2% | 58 | Above Fair Value | 7.2% | — |
| SOLARA SOLARA ACTIVE PHA SCI LTD | +106.8% | 75 | Below Fair Value | 0.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for WINDLAS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. WINDLAS BIOTECH LIMITED (WINDLAS.NS) trades at 867.55 vs a model fair value of 473.08, a gap of -45.5%. Piotroski F-score: 5/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of WINDLAS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for WINDLAS →
Compare
Head-to-head with peers
Compare WINDLAS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse WINDLASNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.